rts logo

Will Vertex Pharmaceuticals, Inc. (VRTX) benefit from Wall Street bulls Calls?

Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) is 18.77% higher on its value in year-to-date trading and has touched a low of $323.02 and a high of $486.42 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The VRTX stock was last observed hovering at around $483.04 in the last trading session, with the day’s gains setting it 0.24%.

Currently trading at $483.28, the stock is 7.03% and 14.43% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.25 million and changing 0.05% at the moment leaves the stock 22.04% off its SMA200. VRTX registered 45.31% gain for a year compared to 6-month gain of 36.54%.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The stock witnessed a 15.34% loss in the last 1 month and extending the period to 3 months gives it a 16.60%, and is 2.79% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 1.70% over the week and 1.91% over the month.

Vertex Pharmaceuticals, Inc. (VRTX) has around 5400 employees, a market worth around $124.71B and $10.17B in sales. Current P/E ratio is 31.35 and Fwd P/E is 26.79. Profit margin for the company is 39.51%. Distance from 52-week low is 49.61% and -0.65% from its 52-week high. The company has generated returns on investments over the last 12 months (20.86%).

The EPS is expected to grow by 10.71% this year.

Vertex Pharmaceuticals, Inc. (VRTX) Top Institutional Holders

The shares outstanding are 257.70M, and float is at 257.36M with Short Float at 1.46%.

Vertex Pharmaceuticals, Inc. (VRTX) Insider Activity

The most recent transaction is an insider sale by WAGNER CHARLES F JR,the company’sEVP & Chief Financial Officer. SEC filings show that WAGNER CHARLES F JR sold 3,250 shares of the company’s common stock on Jun 03 ’24 at a price of $460.00 per share for a total of $1.5 million. Following the sale, the insider now owns 47137.0 shares.

Vertex Pharmaceuticals, Inc. disclosed in a document filed with the SEC on Jun 03 ’24 that Tatsis Ourania (EVP, Chief Reg. & Quality Off.) sold a total of 2,175 shares of the company’s common stock. The trade occurred on Jun 03 ’24 and was made at $460.00 per share for $1.0 million. Following the transaction, the insider now directly holds 49098.0 shares of the VRTX stock.

Still, SEC filings show that on May 31 ’24, Tatsis Ourania (EVP, Chief Reg. & Quality Off.) disposed off 2,250 shares at an average price of $445.00 for $1.0 million. The insider now directly holds 51,273 shares of Vertex Pharmaceuticals, Inc. (VRTX).

Related Posts